

# Performance of the medical device LHAC1 (hyaluronic acid - collagenase) for the management of chronic venous ulcers

<b>Submission date</b> 23/01/2012	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 22/02/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 09/09/2014	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Venous ulcers are extremely common, affecting about 1% of the worlds population, and their impact on cost of healthcare and the lives of the subjects is quite significant. This study aims to assess the performance and tolerability of the medical device LHAC1 (hyaluronic acid - collagenase) for the management of chronic venous ulcers.

### Who can participate?

Patients between 18 and 80 years of age with chronic venous ulcers.

### What does the study involve?

At baseline, all subjects were enrolled to receive LHAC1. A layer of about 2 mm of LHAC1 should be applied on the wound bed once a day. Study treatment continued until complete wound debridement or for a maximum of 20 days.

### What are the possible benefits and risks of participating?

All participants will receive the described treatment, which may reduce necrotic area of the wound bed. There are no known serious risks to participants.

### Where is the study run from?

This study has been conducted in four different centers in Romania: Spitalul Universitar Elias, Spitalul Clinic Dermato-Venerice, Spitalul Clinic Municipal and Spitalul Clinic Judetean Craiova.

### When is the study starting and how long is it expected to run for?

The study ran from February to November 2010.

### Who is funding the study?

Fidia Farmaceutici S.p.A. (Italy).

Who is the main contact?  
Dr Nicola Giordan  
ngiordan@fidiapharma.it

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Victor Clatici

**Contact details**  
Spitalul Universitar Elias  
Bd. Marasti, nr. 17  
Bucuresti  
Romania  
011461  
claticiv@yahoo.com

## Additional identifiers

**Protocol serial number**  
Prot. LHAC1-05

## Study information

**Scientific Title**  
Multicenter, open label, clinical trial on the performance and tolerability of the medical device LHAC1 (hyaluronic acid - collagenase) for the management of chronic venous ulcers

**Study objectives**  
To evaluate the performance and tolerability of the LHAC1 medical device for the excision of chronic venous ulcers in the wound bed preparation phase.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
Romanian Health Ministry, 26/11/2008, ref: 12 din 28.12.2009

**Study design**  
Multicenter open-label study

**Primary study design**  
Interventional

**Study type(s)**

## Treatment

### Health condition(s) or problem(s) studied

Chronic venous ulcers

### Interventions

A layer of about 2 mm thickness of LHAC1 (HA-Collagenase) was applied on the wound bed once a day.

Treatment continued until complete wound debridement or for a maximum period of 20 days. Prior to application the wound was cleansed of debris by gently rubbing with a gauze pad saturated with normal saline solution, or with the desired cleansing agent compatible with collagenase. Dry wounds had to be moistened with physiological saline (0.9% NaCl) or glucose solution prior to treatment. The treatment had to be covered using a non-occlusive dressing to assure the contact with the wound surface.

Five visits were scheduled:

Visit one: enrolment and start of therapy

Visit two: during study treatment

Visit three: during study treatment

Visit four: during study treatment

Visit five: patient final evaluation

At each visit, the following assessments were performed:

1. Physical examination
2. Vital signs
3. Device performance evaluation
4. Concomitant medications/treatments
5. Safety evaluation
6. Compliance
7. Device application

These were measured at day 0 (baseline), day 5 (visit 1), day 10 (visit 2), day 15 (visit 3), day 20 (visit 4 - final visit).

At visit five, we also performed laboratory tests.

### Intervention Type

Device

### Phase

Not Applicable

### Primary outcome(s)

Number of subjects (%) with complete debridement (final debridement or final visit vs baseline) evaluated by using the following five-points scale:

1=100% reduction

2= presence of less than 25% of necrotic tissue

3= presence of 26% to 50% of necrotic tissue

4= presence of 51% to 74% of necrotic tissue

5= presence of 75% to 100% of necrotic tissue

where the points 1 and 2 were considered a complete debridement rating.

This scale was used for the final data analysis and on the basis of measurements obtained during the trial by tracing the wound necrotic area by grid.

### **Key secondary outcome(s)**

1. Reduction percentage of necrotic area
2. Status of the wound bed (non-necrotic/clean area) and periwound skin
3. Overall final judgments

### **Completion date**

18/11/2010

## **Eligibility**

### **Key inclusion criteria**

1. Both sexes, all ethnic backgrounds, both ambulatory and hospitalized
2. Subjects between 18 and 80 years of age
3. Subjects with a diagnosis of chronic venous ulcers (CEAP classification: C6) with areas (or scattered areas) of necrosis (non-viable soft tissue/slough) more than 40%
4. Subjects who have a venous leg ulcer of at least 6 months duration
5. Subjects who have a target wound which is between 2 cm squared to 25 cm squared in area at the baseline assessment
6. Subjects, who are, in the opinion of the Investigator, able to understand this study, cooperate with the study procedures and are willing to return to the centre for all the required visits
7. Subjects who have given their written informed consent in accordance with provisions of pertinent excerpt from the Declaration of Helsinki (revised October 2008) and the Romanian laws

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

### **Sex**

All

### **Key exclusion criteria**

1. Subjects with venous leg ulcer with presence of black eschar
2. Subjects who have exposed bone, tendon or fascia visible around the target wound
3. Subjects who have an Ankle Brachial Pressure Index lower than 0.8 (ABPI/ABI < 0.8), measured by Doppler sonography, absent pulses and peripheral arterial disease
4. Subjects using occlusive wound dressings. The elastocompressive bandages are allowed
5. Concomitant use of local antibiotics, hydrogels, hydrocolloids (the administration of oral antibiotics in presence of infection is allowed)

6. Concomitant use of detergents, hexachlorophene, acid solutions, antiseptics containing heavy metal ions (such as mercury, silver, cobalt, magnesium and manganese), or soaks containing metal ions or acidic solutions (such as Burow's aluminium acetate solution)
7. Concomitant use of disinfectants containing quaternary ammonium
8. Subjects with a known hypersensitivity to collagenase or hyaluronic acid
9. Immunocompromised subjects; known seropositivity to human immunodeficiency virus (HIV)
10. Subjects affected by severe renal, dismetabolic or hepatic failure which represents a risk to the subjects
11. Presence of underlying medical conditions that might interfere with study completion, e.g. end-stage malignant disease, unstable diabetes mellitus, aplastic anaemia, sclerodermia, severe obesity (Body Mass Index > 35), cachexia and recent burns
12. Participation in any other study involving investigational or marketed products concomitantly or within one month prior to study entrance
13. A history of alcoholism, treatment abuse, psychological or other emotional problems that could invalidate informed consent or limit the subject's compliance with protocol requirements
14. Females who are pregnant, lactating or who have not reached menopause and are not abstinent or practising an acceptable means of birth control as determined by the Investigator for the duration of the study
15. Necessity to have a concomitant therapy with any treatment mentioned in the restrictions
16. Subjects unlikely to be compliant/cooperative during the study, in the judgment of the Investigator

**Date of first enrolment**

02/02/2010

**Date of final enrolment**

18/11/2010

## **Locations**

**Countries of recruitment**

Romania

**Study participating centre**

**Spitalul Universitar Elias**

Bucuresti

Romania

011461

## **Sponsor information**

**Organisation**

Fidia Pharmaceutical [Fidia Farmaceutici S.p.A.] (Italy)

**ROR**

<https://ror.org/00dy5wm60>

## **Funder(s)**

### **Funder type**

Industry

### **Funder Name**

Fidia Pharmaceutical [Fidia Farmaceutici S.p.A.] (Italy)

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

#### **IPD sharing plan summary**

Not provided at time of registration